Chart Events
Performance Outlook
| Previous Close | 40.20 |
| Open | 39.93 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 39.72 - 40.15 |
| 52 Week Range | 35.04 - 47.15 |
| Volume | 1,141,792 |
| Avg. Volume | 902,993 |
| Market Cap | 274.656B |
| Beta (5Y Monthly) | 0.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.14 (2.83%) |
| Ex-Dividend Date | Mar 19, 2020 |
| 1y Target Est | 50.10 |
- Investor's Business Daily
Pharmaceutical Industry Leaders Target Cutting-Edge MS Treatments That Once Were 'Fantasy'
Multiple sclerosis can be crippling. But pharmaceutical industry leaders like Biogen, Novartis and Merck are working on MS treatments once only a "fantasy."
- PR Newswire
Roche receives FDA approval for the cobas EGFR Mutation Test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in patients with non-small cell lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of expanded claims for the cobas® EGFR Mutation Test v2 as a companion diagnostic (CDx) for a broad group of therapies in the treatment of non-small cell lung cancer (NSCLC). This claim expansion allows the test to be used as a CDx for all five currently FDA-approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapies targeting EGFR mutations L858R and Exon 19 Deletions in accordance with the approved therapeutic product labeling. The group claim will also enable the test to be used as a CDx for any future approved EGFR TKI therapies targeting the same mutations, without the need to conduct individual clinical studies with the test for each new therapy.
- Zacks
Blueprint Medicines (BPMC) Q3 Earnings Beat, Revenues Rise Y/Y
Blueprint Medicines' (BPMC) both bottom and the top line trump estimates in Q3. Ayvakit's sales rise sequentially.
